TherapeuticsMD Inc. (TXMD) Outlook Starting To Look Brighter?


    BlackRock Fund Advisors has recently announced that it has increased stake in TherapeuticsMD Inc. (NASDAQ:TXMD) by 11.76%. After grabbing 18.27 million shares, the institutional investor is now in possession of 1.92 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.73% having worth around $33.8 million. Moreover, GMT Capital Corp. increased its share by 0.85 million to have a control over 5.99 million shares.

    TherapeuticsMD Inc. (TXMD) concluded trading on 08/27/20 at a closing price of $1.45, with 2.01 million shares of worth about $2.91 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -13.69% during that period and on Thursday the price saw a loss of about -2.03%. Currently the company’s common shares owned by public are about 271.88M shares, out of which, 238.66M shares are available for trading.

    A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the TXMD stock and their offered price forecasts bring an average price target of $6.90. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $13.00 and could fall to a lowest price of $1.20. Analysts also issued an outlook of 2.20 for the TherapeuticsMD Inc. stock for next 12 months. However, touching the estimated high of $13.00 would mean a gain of 88.85% for the stock.

    According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 15 times over the past 12 months. They bought 760,700 shares in 14 of the transactions. In 1 selling transactions, insiders dumped 300,000 shares.

    T Rowe Price Small Cap Stock Fund, Fidelity Series Large Cap Stock F, and Vanguard Total Stock Market Index are the top 3 mutual funds which are holding stakes in TherapeuticsMD Inc. T Rowe Price Small Cap Stock Fund is currently holding 9.15 million shares of worth totaling $16.93 million. The company recently came selling 35300.0 shares which brought its stake up to 3.37% of the company’s outstanding shares. Vanguard Total Stock Market Index, after buying 6.73 million shares, have now control over 2.48% of the stake in the company. It holds 0.0 shares of worth $12.46 million.

    TherapeuticsMD Inc. (NASDAQ: TXMD) started trading at $1.49, above $0.01 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $1.45, or with a loss of -2.03%. Stock saw a price change of -13.69% in past 5 days and over the past one month there was a price change of -26.02%. Year-to-date (YTD), TXMD shares are showing a performance of -40.08% which decreased to -46.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.85 but also hit the highest price of $4.32 during that period. While comparing its average daily trading volume of 5.11 million shares, we see that about 2.01 million changed hands on the day. The stock is currently trading -14.18% below its 20-day simple moving average (SMA20), while that difference is down -9.66% for SMA50 and it goes to -17.59% lower than SMA200.

    BlackRock Fund Advisors acquired 18.27 million shares of TherapeuticsMD Inc. having value of about $33.8 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 1.92 million shares in the company valued at close to $2786694.1, or have control over 11.76% stake in the company. TherapeuticsMD Inc. (NASDAQ: TXMD) currently have 271.88M outstanding shares and institutions hold larger chunk of about 56.90% of that. Holding of mutual funds in the company is about 24.11% while other institutional holders and individual stake holders have control over 33.42% and 15.02% of the stake respectively.

    The stock has a current market capitalization of $427.98M and its 3Y-monthly beta is at 2.25. It has posted earnings per share of -$0.72 in the same period. It has Quick Ratio of 3.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXMD, volatility over the week remained 6.13% while standing at 7.16% over the month.

    Analysts are in expectations that TherapeuticsMD Inc. (TXMD) stock would likely to be making an EPS of -$0.14 in the current quarter, while forecast for next quarter ESPS is -$0.11 and it is -$0.31 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.14 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.13 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -21.30% while it is estimated to increase by 51.60% in next year. EPS is likely to grow at an annualized rate of 21.80% for next 5-years, compared to annual growth of -14.60% made by the stock over the past 5-years.

    Analysts at 9 brokerage firms have issued recommendations for the TherapeuticsMD Inc. (TXMD)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.20. Out of those 9 Wall Street analysts, 7 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.

    Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on August 07, 2020 offering an Underperform rating for the stock and assigned a target price of to it. Coverage by JP Morgan stated TherapeuticsMD Inc. (TXMD) stock as a Neutral in their note to investors on May 19, 2020, suggesting a price target of for the stock. On December 02, 2019, Guggenheim Initiated their recommendations, while on October 17, 2019, H.C. Wainwright Initiated their ratings for the stock with a price target of $7. Stock get an Outperform rating from Noble Capital Markets on April 30, 2019.


    Please enter your comment!
    Please enter your name here